Skip to main content
To the Editor: A consensus exists that schizophrenia is not a single disease, but the final pathway of a variety of still unknown neurobiological derangements. Several treatable autoimmune brain disorders have been identified that present with psychotic symptoms that, in some cases, resemble those found in schizophrenia (1). Antibodies target synaptic proteins, interrupting synaptic transmission in brain networks supporting cognition and emotion. Particularly relevant are autoantibodies against the NR1 subunit of the N-acetyl methyl d-aspartate (NMDA) receptor, which result in diminished NMDA receptor activity, now considered a hallmark of schizophrenia (2). In patients harboring these antibodies, initial psychiatric symptoms are usually followed by dyskinetic movements or seizures and decreased respiratory drive, with a reduced level of consciousness often requiring intensive care (1). However, it could be postulated that a limited form of the disease may result in a milder syndrome akin to schizophrenia. We tested this hypothesis using serum from patients with a first psychotic episode referred to the regional psychiatric center of the province of Alava, Spain, and from healthy comparison subjects. All participants were enrolled after giving written informed consent according to protocols approved by the local institutional review board. Blood was drawn and sera were frozen for subsequent study, blinded to patient-control status. After a 1-year follow-up, sera of patients who then met DSM-IV-TR criteria for schizophrenia spectrum disorders were tested for antibodies to NR1 and other cell surface antigens using three criteria (immunohistochemistry on rat brain slices and dissociated rodent hippocampal neurons, and a cell-based assay in which human embryonic kidney cells recombinantly express NMDA receptor), as previously reported (1). Patients (N=80) and healthy comparison subjects (N=40) did not differ statistically in age (mean age=29.4 years [SD=9.9] and 30.7 years [SD=9.4], respectively) or sex (28% and 38% women, respectively). Anti-NR1 IgG antibodies were not detected in either group. Both groups had four cases with sera reactive to other still unidentified neuronal surface antigens. Our findings and a study of seven patients with schizophrenia (3) fail to support the hypothesis that NMDA receptor IgG antibodies are present in the sera of patients with schizophrenia. Although another study (4) reported NMDA receptor antibodies in the sera of some schizophrenia patients, it was performed without a control group, and test specificity was lower (only one of the above criteria was applied); differences in the clinical diagnosis could also explain the discrepant findings. It should be noted, however, that our study does not rule out the possibility that some patients have antibodies in only the cerebrospinal fluid, but not in serum (1). Additionally, antibodies could be present in patients with acute psychosis not meeting DSM-IV-TR criteria at 1 year.

References

1.
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR: Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091–1098
2.
Moghaddam B, Javitt D: From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012; 37:4–15
3.
Rhoads J, Guirgis H, McKnight C, Duchemin AM: Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia. Schizophr Res 2011; 129:213–214
4.
Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, Coles AJ, Vincent A, Lennox BR: Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011; 258:686–688

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1120 - 1121
PubMed: 23032395

History

Accepted: July 2012
Published online: 1 October 2012
Published in print: October 2012

Authors

Details

Joseph C. Masdeu, M.D., Ph.D.
Ana GonzáLez-Pinto, M.D., Ph.D.
Carlos Matute, Ph.D.
Sonia Ruiz De Azúa, Ph.D.
A. Palomino, Ph.D.
Jose De Leon, M.D.
Karen F. Berman, M.D.
Josep Dalmau, M.D., Ph.D.
Barcelona, Spain; Philadelphia

Competing Interests

Presented at the 67th annual meeting of the Society of Biological Psychiatry, Philadelphia, May 3–5, 2012.

Funding Information

Dr. Dalmau has a patent on a procedure to determine anti-NMDA antibodies and receives royalties from Euroimmun, a company that provides this procedure commercially. The other authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share